Literature DB >> 27504306

A Retrospective Study of the Treatment Outcome of Drug Therapies used in Heart Failure Patients with Associated Co-morbidities in a Tertiary Care Hospital.

Harish Thanusubramanian1, Meena Kumari Kamal Kishore2, Ranjan Shetty3, Mohan Babu Amberkar2.   

Abstract

INTRODUCTION: Heart failure is one of the most common heart problems seen in the Indian population. There are various drugs used to prevent further progression of the disease. In India, there are few studies in relation to treatment outcome in a tertiary care hospital. AIM: To study the treatment outcome of drug therapies used in heart failure patients with associated co-morbidities in a tertiary care hospital.
MATERIALS AND METHODS: This was an observational study conducted on 250 patients with heart failure. Details collected using the proforma were demography (age, gender); medical history; medication history for heart failure patients on admission and discharge; ejection fraction; median length of stay in hospital; number of readmissions & in-hospital mortality.
RESULTS: One hundred and twenty eight patients categorized into LVSD group (ejection fraction <40%) and 122 patients in PSF group (ejection fraction > 40%). Medical history of coronary artery disease (54%) was significantly higher in LVSD group (p<0.05) and anaemia (19%) was significantly higher in PSF group (p<0.05). On admission, inotropes (30%), digoxin (59%) and statins (54%) were prescribed more in LVSD patients (p<0.05) while calcium channel blockers (20%) were prescribed more in PSF group (p<0.05). At discharge, patients with LVSD were receiving ACE inhibitors (51%), beta blockers (30%), digoxin (67%) and statins (59%) (p<0.05) while calcium channel blockers (20%) was prescribed more in PSF group. The median length of stay was slightly higher in patients with PSF (7 days) as compared to LVSD (6 days). In-hospital mortality was lower in patients with PSF (6%) than patients with LVSD (20%). The percentage of readmissions within one month was slightly higher in patients with PSF (15%) compared to LVSD (14%).
CONCLUSION: Length of stay in hospital was 6-7 days in heart failure patients. In hospital mortality in LVSD patients (20%) was higher compared to PSF patients (6%). A 15% heart failure patient were readmitted within 1month of discharge.

Entities:  

Keywords:  Diabetes mellitus; Hypertension; In-hospital mortality; Readmissions

Year:  2016        PMID: 27504306      PMCID: PMC4963666          DOI: 10.7860/JCDR/2016/18636.7989

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

1.  Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.

Authors:  Benjamin A Steinberg; Xin Zhao; Paul A Heidenreich; Eric D Peterson; Deepak L Bhatt; Christopher P Cannon; Adrian F Hernandez; Gregg C Fonarow
Journal:  Circulation       Date:  2012-05-21       Impact factor: 29.690

Review 2.  Heart failure: epidemiology and prevention in India.

Authors:  Mark D Huffman; Dorairaj Prabhakaran
Journal:  Natl Med J India       Date:  2010 Sep-Oct       Impact factor: 0.537

3.  Hospitalization of patients with heart failure: a population-based study.

Authors:  M R Cowie; K F Fox; D A Wood; C Metcalfe; S G Thompson; A J S Coats; P A Poole-Wilson; G C Sutton
Journal:  Eur Heart J       Date:  2002-06       Impact factor: 29.983

4.  Hypertensive heart failure: patient characteristics, treatment, and outcomes.

Authors:  Frank Peacock; Alpesh Amin; Christopher B Granger; Charles V Pollack; Phillip Levy; Richard Nowak; Kurt Kleinschmidt; Joe Varon; Allison Wyman; Joel M Gore
Journal:  Am J Emerg Med       Date:  2010-05-01       Impact factor: 2.469

Review 5.  Epidemiology and risk profile of heart failure.

Authors:  Anh L Bui; Tamara B Horwich; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2010-11-09       Impact factor: 32.419

6.  Patterns of comorbidity in older adults with heart failure: the Cardiovascular Research Network PRESERVE study.

Authors:  Jane S Saczynski; Alan S Go; David J Magid; David H Smith; David D McManus; Larry Allen; Jessica Ogarek; Robert J Goldberg; Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2013-01       Impact factor: 5.562

7.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

Authors:  Gregg C Fonarow; Wendy Gattis Stough; William T Abraham; Nancy M Albert; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

8.  Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

Authors:  Barry H Greenberg; William T Abraham; Nancy M Albert; Karen Chiswell; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young; Gregg C Fonarow
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

9.  Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States.

Authors:  Padma Kaul; Shelby D Reed; Adrian F Hernandez; Jonathan G Howlett; Justin A Ezekowitz; Yanhong Li; Yinggan Zheng; Jean L Rouleau; Randall C Starling; Christopher M O'Connor; Robert M Califf; Paul W Armstrong
Journal:  JACC Heart Fail       Date:  2013-10-23       Impact factor: 12.035

Review 10.  Congestive heart failure in Indians: how do we improve diagnosis & management?

Authors:  S Reddy; A Bahl; K K Talwar
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

View more
  1 in total

1.  Simvastatin Inhibits IL-1β-Induced Apoptosis and Extracellular Matrix Degradation by Suppressing the NF-kB and MAPK Pathways in Nucleus Pulposus Cells.

Authors:  Ji Tu; Wentian Li; Yukun Zhang; Xinghuo Wu; Yu Song; Liang Kang; Wei Liu; Kun Wang; Shuai Li; Wenbin Hua; Cao Yang
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.